Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Appointed director
Asset disposition
Class action filed
Cellectar Biosciences, Inc. (CLRB) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
10/02/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/21/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
08/14/2023 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update FLORHAM PARK, N.J., August 14, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. Second Quarter and Recent Corporate Highlights"
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/29/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Appendix A"
06/28/2023 4 Swirsky Douglas J (Director) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 37,500 options to buy @ $1.85, valued at $69.4k
06/28/2023 4 NEIS JOHN (Director) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 25,000 options to buy @ $1.85, valued at $46.3k
06/28/2023 4 Loren Stefan (Director) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 25,000 options to buy @ $1.85, valued at $46.3k
06/28/2023 4 DRISCOLL FREDERICK W (Director) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 25,000 options to buy @ $1.85, valued at $46.3k
06/28/2023 4 Chanan-Khan Asher (Director) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 25,000 options to buy @ $1.85, valued at $46.3k
05/04/2023 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update FLORHAM PARK, N.J., May 4, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. First Quarter and Recent Corporate Highlights"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/28/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
03/16/2023 4 Shustov Andrei (Senior Vice President, Medical) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 100,000 options to buy @ $1.67, valued at $167k
03/16/2023 3 Shustov Andrei (Senior Vice President, Medical) has filed a Form 3 on Cellectar Biosciences, Inc.
03/16/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
03/09/2023 8-K Quarterly results
Docs: "Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update FLORHAM PARK, N.J., Mar. 9, 2023 -- Cellectar Biosciences, Inc. , a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the year ended December 31, 2022 and provided a corporate update. Fourth Quarter and Recent Corporate Highlights"
03/09/2023 10-K Annual Report for the period ended December 31, 2022
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/18/2023 4 Longcor Jarrod (COO) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 144,000 options to buy @ $1.68, valued at $241.9k
01/18/2023 4 CARUSO JAMES V (President and CEO) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 261,000 options to buy @ $1.68, valued at $438.5k
01/18/2023 4 Kolean Chad J (CFO) has filed a Form 4 on Cellectar Biosciences, Inc.
Txns: Granted 104,000 options to buy @ $1.68, valued at $174.7k
01/04/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
12/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/15/2022 3 Form 3 - Initial statement of beneficial ownership of securities:
12/05/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/05/2022 EFFECT Form EFFECT - Notice of Effectiveness:
12/02/2022 8-K Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financi...
Docs: "AMENDED AND RESTATED BY-LAWS OF",
"DIRECTOR AND OFFICER INDEMNIFICATION AGREEMENT"
11/23/2022 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
11/02/2022 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy